EpiAxis
  • Home
  • About us
    • Introduction
    • Board
    • Management & advisers
    • Collaborators
  • Our science
    • Epigenetics & cancer simplified
    • EpiAxis science in detail
    • Our pipeline & IP
    • Clinical trial
    • Publications
  • Our news
  • Contact
Select Page

Publications

2022 – A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED)

2020 –  Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via Novel LSD1-EOMES Switch

2020 – Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response

2019 – Immune modulation via epigenetic targeting to overcome immune checkpoint inhibitor resistance

2019 – Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer

2018 – LSD1 Activation Promotes Inducible EMT Programs and Modulates the Tumour Microenvironment in Breast Cancer

2016 – Identification of chromatin accessibility domains in human breast cancer stem cells

Copyright © 2021 - EpiAxis Therapeutics | Privacy Policy